← Back

Cencor: Cencora's Strong Q1 Performance Driven by OneOncology Acquisition

Cencora, Inc. reported a robust fiscal 2026 first quarter, with adjusted diluted EPS of $4.08, beating analyst estimates of $4.05. The company's consolidated revenue reached $85.9 billion, representing a 5.5% increase, driven by growth in both reportable segments. The US healthcare solutions segment revenue was $76.2 billion, up 5%, with operating income surging 21% to $831 million. The international healthcare solutions segment revenue grew approximately 10% on an as-reported basis and 6% on a constant currency basis to $7.6 billion.

COR

USD 334.71

-3.23%

A-Score: 5.9/10

Publication date: February 4, 2026

Full Report

Author: Analystock.ai

📋 Highlights
  • Adjusted Operating Income Growth: Rose 12% to $831 million in Q1, driven by strong US healthcare solutions performance and the OneOncology acquisition.
  • Revenue Expansion: Consolidated revenue hit $85.9 billion (+5.5%), with US healthcare solutions contributing $76.2 billion (+5%) and international solutions up 10% ($7.6 billion).
  • Guidance Upgrade: Fiscal 2026 revenue growth now projected at 7–9%, with operating income growth raised to 11.5–13.5% and adjusted EPS guidance of $17.45–$17.75.
  • OneOncology Impact: Acquisition contributed $35 million in net after-tax earnings Q1, with full-year operating margin expected to rise from 9% to 16% due to integration benefits.
  • Interest Expense Rise: Projected to increase to $480–$500 million in FY2026, doubling Q1’s interest expense of $240 million due to OneOncology financing costs.

Segment Performance

The US segment's operating income growth was 21% in Q1, driven by the OneOncology acquisition and continued strong performance in the US healthcare solutions segment. Excluding RCA and OneOncology, the US segment's performance is within the long-term guidance range of 7-10%. The company expects utilization trends, strength in specialty sales, and broad-based performance to drive growth.

Guidance and Outlook

Cencora raised its fiscal 2026 guidance, expecting consolidated revenue growth to be in the range of 7% to 9%, and consolidated operating income growth to be in the range of 11.5% to 13.5%. The company expects adjusted diluted EPS to be in the range of $17.45 to $17.75. The acquisition of OneOncology is expected to be neutral, net of financing costs, to adjusted diluted EPS in its first twelve months.

Valuation and Metrics

With a P/E Ratio of 39.43 and an EV/EBITDA of 18.39, the market appears to be pricing in significant growth expectations. The company's ROIC of 13.83% and ROE of 101.43% indicate strong profitability. The Net Debt / EBITDA ratio of 1.62 suggests a manageable debt burden. Analysts estimate next year's revenue growth at 6.7%, which may be challenging to achieve given the current valuation multiples.

Acquisition Impact

The OneOncology acquisition is expected to drive growth, with benefits flowing into the segment level throughout the year. The company owns 92% of OneOncology, with the remaining 8% owned by practices and management. The $30 million below-the-line item related to OneOncology is an ongoing non-controlling interest piece.

Capital Deployment

Cencora has paused share repurchases, focusing on deleveraging, but long-term capital deployment priorities remain the same, including investing in the business, strategic acquisitions, share repurchases, and a growing dividend. The company's dividend yield is 0.68%, which is relatively modest compared to other industry players.

Cencor's A-Score